COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs
Jaguar Health, Inc. announces FDA conditional approval renewal of Canalevia-CA1 for chemotherapy-induced diarrhea in dogs. Canalevia-CA1, a crofelemer tablet, is available from major U.S. veterinary distributors -
-
-
COMMUNIQUÉ DE PRESSE
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)
Napo Pharmaceuticals announces acceptance of late-breaking abstract on crofelemer results for breast cancer patients in OnTarget trial, presented at SABCS 2024 -
-
-
COMMUNIQUÉ DE PRESSE
Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting
Napo Pharmaceuticals announces abstracts for two investigator-initiated studies on crofelemer for chronic refractory diarrhea patients, presented at ACG 2024. Jaguar CEO Lisa Conte comments on crofelemer's clinical robustness and impact on IBS-D patients
